IASLC > International Association for the Study of Lung Cancer > Conferences & Events > Event Details
Locally Advanced NSCLC: Where Are We, Where Do We Go From Here?
May 09, 2017 | Online


This webinar will provide an updated overview of current standard therapies for stage III NSCLC.  It will also review the most recent data and current trials likely to impact standards of care.  

Program Objectives:

  • Increase clinician awareness of novel immunotherapeutic and targeted biologic agents that have demonstrated activity in stage IV NSCLC and may be appropriate candidates for clinical trials in earlier stages of disease
  • Review current management of stage III NSCLC, including combined modality approaches and the potential use of immunotherapy, or targeted biologic agents
  • Identify ongoing clinical trials that are likely to impact patient care in the near future

What you should expect to learn

After viewing this program, attendees will:

  • have a better understanding of current data supporting standard chemoradiotherapy regimens for locally advanced NSCLC;
  • be able to discuss the rationale for clinical trials evaluating the integration of immunotherapies into standard treatment paradigms;
  • have an awareness of the preliminary data emerging from combined modality trials incorporating immunotherapy for stage III NSCLC;
  • be able to address the use of targeted therapies in the setting of stage locally advanced disease.

Everett E. Vokes, MD

John E. Ultmann Professor
Chairman, Department of Medicine
University of Chicago 
Medicine and Biological Sciences


Ramaswamy Govindan, MD - Program Chair

Co-Director, Section of Medical Oncology
Professor of Medicine
Anheuser-Busch Endowed Chair in Medical Oncology
Director, Section of Oncology
Washington University School of Medicine